found no association between genetically proxied triglyceride levels and ischemic stroke or its subtypes.42 While no triglyceride-lowering agents have demonstrated efficacy in cardiovascular outcome trials, several drug mechanisms are under active investigation including inhibition of Angiopoietin-like 3 (ANGPTL3), ANGPTL4, and Apolipoprotein C3 (APOC3). The gene discussed is ANGPTL3; the disease is ischemic stroke.